Advertisement

Bulletin of Experimental Biology and Medicine

, Volume 140, Issue 4, pp 435–438 | Cite as

Protective Effect of Reamberin on Functional Activity of Mitochondria during Skin Ischemia

  • V. P. Galenko-Yaroshevskii
  • A. V. Agadzhanova
  • K. O. Fedorovich
  • N. V. Lapina
  • A. S. Gorelashvili
  • T. M. Berberashvili
  • G. V. Sukoyan
Article
  • 41 Downloads

Abstract

Reamberin in a dose of 25 mg/kg (succinate concentration) was injected intravenously for 3 days starting from the 1st hour after skin ischemia modeling. This treatment decreased activities of lactate dehydrogenase, aspartate transaminase, and creatine phosphokinase in skin homogenates by 1.6 times, 19%, and 51.3%, respectively. The index of cytolysis decreased by 18%. Reamberin had an energotropic effect, which manifested in an increase in the total ATP content and concentration of creatine phosphate (by 16 and 10%, respectively). After administration of Reamberin, activity of the succinate-ubiquinone reductase system increased by 17%. Under these conditions succinate dehydrogenase activity exceeded the normal by 21%. Reamberin had no effect on the mitochondrial NADH-ubiquinone reductase system in dermal cells during skin ischemia. Superoxide dismutase activity in the area of necrosis increased to the control level on day 3 of treatment with Reamberin. Activities of catalase and glutathione peroxidase increased by 13 and 19%, respectively. Our results indicate that the course of intravenous treatment with Reamberin for 3 days contributes to an increase in reserve capacities of the antioxidant protection system and produces a protective effect during skin ischemia.

Key Words

skin ischemia mitochondria energotropic effect Reamberin antioxidant protection system 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    V. P. Galenko-Yaroshevskii, E. N. Bagmetova, I. A. Fil'chukova, et al., Byull. Eksp. Biol. Med., 139, No.2, 170–174 (2005).Google Scholar
  2. 2.
    P. A. Galenko-Yaroshevskii, I. S. Chekman, and N. N. Gorchakova, Essays on Pharmacology of Drugs for Metabolic Therapy [in Russian], Moscow (2001).Google Scholar
  3. 3.
    A. L. Kovalenko and M. G. Romashov, Remaberin, 1.5% Solution for Injections: from the Experiment to Clinics [in Russian], St. Petersburg (1999).Google Scholar
  4. 4.
    N. Chen, Y. Liu, Ch. D. Greiner, and L. Holtzman, J. Lab. Clin. Med., 136, No.1, 58–65 (2000).CrossRefPubMedGoogle Scholar
  5. 5.
    E. Fosslien, Ann. Clin. Lab. Sci., 31, 25–67 (2001).PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2005

Authors and Affiliations

  • V. P. Galenko-Yaroshevskii
    • 1
  • A. V. Agadzhanova
    • 1
  • K. O. Fedorovich
    • 1
  • N. V. Lapina
    • 1
  • A. S. Gorelashvili
    • 2
  • T. M. Berberashvili
    • 2
  • G. V. Sukoyan
    • 1
  1. 1.Krasnodar Branch, Southern BureauRussian Academy of Medical SciencesKrasnodarRussia
  2. 2.N. V. Karsanov Republican Research Center for Medical Biophysics and Implementation of New Biomedical TechnologiesTbilisiGeorgia

Personalised recommendations